

# **HEALTHCARE MONTHLY**

SEPTEMBER 2024

Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

BioTech / Pharma **Healthcare Services** Life Sciences / Diagnostics **Medical Devices** 



## **HEADLINE TRANSACTIONS**

ACQUIROR ACQUISITION SYNOPSIS

Community Oncology Revitalization Enterprise Ventures







- US Oncology Inc., a subsidiary of McKesson Corporation (NYSE:MCK) has entered a definitive agreement to acquire a 70% stake in Community Oncology Revitalization Enterprise Ventures, LLC ("Core Ventures") from Florida Cancer Specialists & Research Institute, LLC
- Core Ventures is a physician-owned MSO specializing in the diagnosis and treatment of cancer
- US Oncology is an oncology practice management company providing integrated cancer services
- · McKesson provides healthcare services across four segments: Domestic Pharmaceutical, Prescription, Surgical and International
- Florida Cancer Specialists & Research provides targeted therapies, genomic-based treatment, immunotherapy and clinical research
- Total Consideration: \$2.5 billion cash (70% stake)



FLORIDA CANCER



- · Johnson & Johnson Inc. (NYSE:JNJ) has entered a definitive agreement to acquire V-Wave Ltd.
- · V-Wave develops implantable therapeutic devices designed to regulate Left Atrial Pressure, the underlying cause of heart failure
- Johnson & Johnson develops pharmaceutical and medical devices across immunology, oncology, neurology, pulmonary, cardiology and metabolic disease areas
- Total Consideration: \$600 million cash: \$1.1 billion earnout





- · The Carlyle Group Inc. (NASD:CG) has entered a definitive agreement to acquire Vantive Health, LLC from Baxter International Inc. (NYSE:BAX)
- · Vantive Health provides renal health equipment including dialysis machines and organ support hardware
- · Carlyle is a Washington DC-based private equity firm with \$435 billion of AUM; Carlyle has invested across all healthcare subsectors
- Baxter International provides medical instruments and supplies for use in care settings such as hospitals and homecare facilities
- · Total Consideration: \$1.4 billion cash






- Bansk Group, Inc. has entered a definitive agreement to acquire PetIQ, Inc. (NYSE:PETQ)
- · PetIQ manufactures and distributes veterinary medicine, OTC pet-focused supplements & hygiene products in addition to delivering preventive veterinary services through pet retail stores
- Bansk is a New York-based private equity firm with \$2.4 billion of AUM; within healthcare, Bansk invests in consumer health
- Total Consideration: \$980 million cash
- Per Share Price Premium: 50,7%




# HEALTHCARE GROWTH & VALUATION TRENDS


#### **Enterprise Value / LTM Revenue**




#### **Enterprise Value / LTM EBITDA**



#### LTM Revenue Growth




#### LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.

#### **LTM Stock Price Index**





# SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Jnana Therapeutics Inc.	Otsuka America Inc.	Jnana develops a drug discovery platform designed to target the solute carrier family of transporters and metabolic gates Total Consideration: \$800 million cash
Revance Therapeutics Inc. (NASD:RVNC)	Crown Laboratories Inc. (Hildred Capital Management, LLC)	Revance Therapeutics is a biotechnology company offering aesthetic therapeutics including neuromodulators, dermal fillers and injectables; its portfolio includes DAXXIFY, a longer-term injectable neurotoxin Total Consideration: \$721 million cash Per Share Price Premium: 88.7%
G1 Therapeutics, Inc. (NASD:GTHX)	Pharmacosmos Therapeutics Inc.	G1 discovers, develops & commercializes small molecule therapeutics for patients with cancer Total Consideration: \$395 million cash Per Share Price Premium: 68.2%
Target	Acquiror	Life Sci / Diagnostics Transactions
LifeLabs Inc. (OMERS Infrastructure Mgmt Inc.)	Acquiror  Quest Diagnostics Inc. (NYS:DGX)	Life Sci / Diagnostics Transactions  LifeLabs provides standard, genetic and naturopathic laboratory testing services for physicians, hospitals and other healthcare providers across Canada Total Consideration: \$1.0 billion cash
LifeLabs Inc. (OMERS Infrastructure	Quest Diagnostics	LifeLabs provides standard, genetic and naturopathic laboratory testing services for physicians, hospitals and other healthcare providers across Canada

Target	Acquiror	Health Services Transactions
R1 RCM Inc. (NASD:RCM)	TowerBrook Capital Partners LP; Clayton, Dubilier & Rice, LLC	R1 RCM is a provider of end-to-end revenue cycle management services for health systems, hospitals and physician groups Total Consideration: \$4.5 billion cash (71% stake) Per Share Price Premium: 11.0%
United Urology Group (Audax Management Company, LLC)	OneOncology, LLC (TPG (NASD:TPG))	United Urology Group is a urology-focused MSO supporting 250 providers and over 1,300 employees in Arizona, Colorado, Delaware, Maryland and Tennessee
Care.ai	Stryker (NYSE:SYK)	Care.ai specializes in providing Al-assisted virtual care and smart room technology
Target	Acquiror	Medical Device Transactions
Paragonix Technologies Inc. (Signet Healthcare Partners, LLC)	Getinge AB (STO:GETI B)	Paragonix Technologies develops organ transportation devices designed for the security and preservation of donor organs Total Consideration: \$477 million cash
Obp Surgical Corp.	CooperSurgical Inc (The Cooper Companies (NASD:COO))	Obp develops single-use medical devices with integrated light sources to assist in plastic, general, spine and minimally invasive surgeries Total Consideration: \$100 million cash
Hobson & Motzer, Inc.	Vantedge Medical (Aterian Investment Partners, LP)	Hobson & Motzer manufactures consumable precision medical devices for the surgical stapler market

### **Selected TM Capital Healthcare Experience**







### TM Capital's Healthcare Industry Contacts



James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



John Dean Director jdean@tmcapital.com 404.995.6234



Paul Smolevitz
Managing Director
psmolevitz@tmcapital.com
212.809.1416



Josh Mastracci Director jmastracci@tmcapital.com 404.924.4562



Steve Hunter Managing Director, Sponsor Coverage shunter@tmcapital.com 404.995.6232

#### ABOUT TM CAPITAL, A DIVISION OF JANNEY

FOUNDED IN 1989 AND NOW PART OF JANNEY MONTGOMERY SCOTT, TM CAPITAL IS THE CLIENT-FIRST INVESTMENT BANKING TEAM ADVISING INDUSTRY-LEADING COMPANIES ACROSS NORTH AMERICA AND AROUND THE WORLD. IN EVERYTHING WE DO, OUR PROFESSIONALS SHARE A RELENTLESS COMMITMENT TO ENGINEERING EXTRAORDINARY OUTCOMES WITH AN UNMATCHED STANDARD OF CLIENT CARE. OVER THE LAST THREE DECADES, WE HAVE COMPLETED NEARLY 450 TRANSACTIONS WITH A COMBINED VALUE OF \$30 BILLION. WITH OFFICES IN ATLANTA, BOSTON AND NEW YORK, OUR MISSION CRITICAL CAPABILITIES INCLUDE: COMPLEX MERGERS AND ACQUISITIONS; DEBT AND EQUITY FINANCINGS; MINORITY AND MAJORITY RECAPITALIZATIONS; RESTRUCTURINGS; AND BOARD ADVISORY SERVICES. TM CAPITAL IS ALSO A MEMBER OF OAKLINS, THE WORLD'S MOST EXPERIENCED MID-MARKET M&A ADVISOR, WITH OVER 850 PROFESSIONALS AND DEDICATED INDUSTRY TEAMS IN MORE THAN 45 COUNTRIES, HAVING CLOSED 1,700 TRANSACTIONS IN THE PAST FIVE YEARS. FOR MORE INFORMATION, PLEASE VISIT WWW.TMCAPITAL.COM.

#### ABOUT JANNE

JANNEY MONTGOMERY SCOTT LLC IS A LEADING FULL-SERVICE INVESTMENT BANKING AND FINANCIAL SERVICES FIRM SERVING INDIVIDUAL, CORPORATE, INSTITUTIONAL AND GOVERNMENT CLIENTS. JANNEY IS AN INDEPENDENTLY OPERATED SUBSIDIARY OF THE PENN MUTUAL LIFE INSURANCE COMPANY, ONE OF THE 15 LARGEST MUTUAL INSURANCE COMPANIES IN THE NATION, AND IS A MEMBER OF THE NEW YORK STOCK EXCHANGE, FINANCIAL INDUSTRY REGULATORY AUTHORITY AND THE SECURITIES INVESTOR PROTECTION CORPORATION.

THIS COMMUNICATION IS THE INTELLECTUAL PROPERTY OF TM CAPITAL, A DIVISION OF JANNEY AND MAY NOT BE REPRODUCED, DISTRIBUTED, OR PUBLISHED BY ANY PERSON FOR ANY PURPOSE WITHOUT JANNEY'S EXPRESS PRIOR CONSENT.

**DISCLAIMER:** This communication has been created by the Investment Banking Department of Janney Montgomery Scott LLC ("Janney") and is to be used for informational purposes only. It is not a product of Janney's Research Department. The information presented herein is taken from sources believed to be reliable but is not guaranteed by Janney as to its accuracy or completeness and is subject to change. The views expressed in this communication reflect the personal views of the author(s) regarding the subject securities and issuers and may differ with those of Janney or Janney's Research Department. This communication shall not constitute a solicitation or offer to purchase or sell a security. This communication is intended for Institutional Use Only, not for retail investors, and should not be distributed, forwarded, or otherwise disseminated. Nothing in this material should be construed as tax, legal, or accounting advice. Please consult your own tax, legal, and accounting professionals. Member: NYSE, FINRA, SIPC.